Halozyme Therapeutic (NASDAQ: HALO) released its earnings data on Monday. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.16) by $0.12. The company had revenue of $21.80 million for the quarter, compared to the consensus estimate of $7.32 million. During the same quarter last year, the company posted ($0.18) earnings per share. Halozyme Therapeutic’s revenue was up 808.3% compared to the same quarter last year.
A number of analysts have recently weighed in on HALO shares. Analysts at Barclays Capital reiterated an “overweight” rating on shares of Halozyme Therapeutic in a research note to investors on Friday, February 1st. They now have a $9.00 price target on the stock. On a related note, analysts at BMO Capital Markets cut their price target on shares of Halozyme Therapeutic from $12.00 to $9.00 in a research note to investors on Friday, February 1st. They now have an “outperform” rating on the stock. Finally, analysts at Wedbush downgraded shares of Halozyme Therapeutic from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, January 30th.
Five equities research analysts have rated the stock with a buy rating, two have assigned a hold rating, and one has assigned a sell rating to the company’s stock. The company has an average rating of “overweight” and an average price target of $9.14.
Shares of Halozyme Therapeutic (HALO) traded down 3.21% during mid-day trading on Monday, hitting $5.72. Halozyme Therapeutic (HALO) has a 52 week low of $3.86 and a 52 week high of $13.50. The stock’s 50-day moving average is currently $7.05. The company’s market cap is $642.4 million.
Halozyme Therapeutics, Inc. is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
